Adolor About
Adolor:
The goal of the company's research effort is to develop products which maintain
or improve opioid-like pain
relief while reducing or eliminating opioid side effects. Entereg™
(alvimopan), is Adolor's lead product candidate Entereg
is a synthetic chemical compound that selectively blocks the interaction of narcotic
analgesics at peripheral mu opioid receptors without blocking the centrally-mediated
analgesic effects. Adolor's
second product candidate is a sterile
lidocaine patch in clinical development for the management of postoperative
incisional pain. Opoid receptor pain targets and
cannabinoid receptor pain targets
Key
Statistics for Adolor
Adolor Corporation is a biopharmaceutical company
specializing in the discovery, development and commercialization of novel prescription
pain management products.
Preclinical
Trials:
More on Adolor:
Basic
Chart for Adolor
Analyst
Opinion
Analysts
Estimates